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Background: Escherichia coli has been a main host for the production of recombinant proteins of biomedical interest,
but conformational stress responses impose severe bottlenecks that impair the production of soluble, proteolytically
stable versions of many protein species. In this context, emerging Generally Recognized As Safe (GRAS) bacterial hosts
provide alternatives as cell factories for recombinant protein production, in which limitations associated to the use of
Gram-negative microorganisms might result minimized. Among them, Lactic Acid Bacteria and specially Lactococcus
lactis are Gram-positive GRAS organisms in which recombinant protein solubility is generically higher and downstream
facilitated, when compared to E. coli. However, deep analyses of recombinant protein quality in this system are
still required to completely evaluate its performance and potential for improvement.
Results: We have explored here the conformational quality (through specific fluorescence emission) and solubility of
an aggregation-prone GFP variant (VP1GFP) produced in L. lactis. In this context, our results show that parameters such
as production time, culture conditions and growth temperature have a dramatic impact not only on protein yield, but
also on protein solubility and conformational quality, that are particularly favored under fermentative metabolism.
Conclusions: Metabolic regime and cultivation temperature greatly influence solubility and conformational
quality of an aggregation-prone protein in L. lactis. Specifically, the present study proves that anaerobic growth is
the optimal condition for recombinant protein production purposes. Besides, growth temperature plays an important
role regulating both protein solubility and conformational quality. Additionally, our results also prove the great
versatility for the manipulation of this bacterial system regarding the improvement of functionality, yield and
quality of recombinant proteins in this species. These findings not only confirm L. lactis as an excellent producer
of recombinant proteins but also reveal room for significant improvement by the exploitation of external protein
quality modulators.
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Obtaining proteins of biotechnological and biomedical
interest from their natural sources is hampered by severe
economic constraints. The emergence of recombinant
DNA technologies allowed developing different gene ex-
pression systems (cell factories) adapted to produce
functional versions of the desired proteins, becoming* Correspondence: Elena.Garcia.Fruitos@uab.cat
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unless otherwise stated.recombinant protein production a routine practice in
the BioPharma industry [1-3]. Among these expression
systems, the bacterium Escherichia coli has been the
principal working horse, because of its well-known gen-
etics and physiology, cost-effective culture and easy scal-
ing up. However, being E. coli a Gram-negative bacterium,
cell wall lipopolysaccharides (LPSs) are generic contami-
nants of the final product and promote not only pyrogen-
icity but also activation of acute inflammatory responses.
The presence of bacterial endotoxins is then one of the
major concerns by regulatory agencies [4], and the need of
adding steps for endotoxin removal turns otherwise sim-
ple processes into practices with high associated costs. Be-
sides, protocols for endotoxin removal can also impair orentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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processes have to meet not only good cost-effectiveness
ratios but also high product quality [6-8], the use of cell
factories other than E. coli is becoming an increasingly
recognized need [3]. In this context, other bacterial groups
are emerging as intriguing alternatives that offer advan-
tages over the use of E. coli regarding protein quality, ab-
sence of endotoxins, disulfide bridge formation and
solubility [9,10]. Lactic Acid Bacteria (LAB) are classified
as Generally Recognized As Safe (GRAS) organisms and
represent appealing possibilities for the production of
safer therapeutic proteins [11,12]. Specifically, Lactococcus
lactis, which has been used for long in food industry, has
emerged as a cost-effective protein cell factory [12]. In
this regard, a wide range of genetic tools adapted to
LAB make nowadays possible to successfully produce
an increasing number of fully LPS-free recombinant
proteins [5,11,13-16]. More specifically, it is worth men-
tioning that three versatile gene expression systems,
named NICE (nisin-controlled expression system) [17],
P170 [18,19] and zinc systems [20], have been developed
for use in L. lactis. Interestingly, L. lactis is also currently
used as a life vector for drug, DNA and other molecules
delivery to mucosal surfaces [15,21-23], proving their huge
potential for its use in human medicine [11]. In addition,
GRAS organisms are being considered for the produc-
tion of diverse bacterial products, not only soluble pro-
teins but also biopolymers, polymeric nanoparticles and
self-assembling protein-based nanoparticles, among
others [24]. For instance, polyhydroxibutirate (PHB) inclu-
sions produced in L. lactis are purer than those obtained
in E. coli [5] and have lower production costs due to the
reduction of the number of downstream processing steps
[5]. In this context, producing endotoxin-free biopoly-
meric beads is critical for use in medical applications
[25,26].
Despite reports on protein production in L. lactis
abound [27], further analyses of protein quality and solu-
bility in this system are required to deeply understand
the host performance regarding protein quality control
and to fully exploit and ever expand, its well-known
properties as a factory for soluble, highly functional pro-
teins. Besides, considering that, although L. lactis is a
facultative anaerobe with a fermentative metabolism, this
microorganism is also able to undergo respiratory
growth when hemin is added to aerated cultures [28],
both growth conditions have also been explored in this
study.
Results
To explore recombinant quality in L. lactis we have
studied the influence of production time and growth
conditions of a wild type strain in the production of an
aggregation-prone fluorescent protein (rVP1GFP) thathas been previously used as a convenient solubility
model in E. coli [29]. The specific emission of GFP has
been successfully used as a marker of conformational
quality of GFP-containing misfolding-prone proteins as
there is a positive linear dependence between conform-
ational quality and the presence of native-like conforma-
tions [30,31].
Growth conditions
Under anaerobic fermentation but not under hemin-
stimulated respiration, protein solubility was compro-
mised rendering fluorescent protein deposits (Figure 1).
This pattern was coincident with that of the formation
of PHB inclusions that occurs only under anaerobiosis
[26]. In fact, cells were not fluorescent under aerobic
conditions (Figure 1), in agreement with previously studies
indicating that hemin-induced cell respiration does not
support the production of functional proteins [32,33].
Therefore, fermentative growth was established as stand-
ard conditions for subsequent experiments.
Production time
The fluorescence emission (Figure 2) and the ratio of
soluble versus insoluble protein (Figure 3) fractions were
determined by fluorimetry and western blot (Figure 4),
respectively. The fluorescence emission does not present
significant differences at different production times.
However, in general terms, it is possible to conclude that
GFP activity increases at longer production times, being
this effect more marked in the soluble fraction (Figure 2).
Besides, it is worh mentioning that at 3 h post-induction,
protein solubility reached 67%, a yield much higher than
that reached in E. coli for the same protein under compar-
able conditions (10-18%, [34]). In this context, the poten-
tial of the system for the soluble protein production was
confirmed with a difficult-to-express human catalase,
which under these conditions majorly occurred at the sol-
uble cell fraction (75%) (data not shown). On the other
hand, the conformational quality, namely the ratio be-
tween protein activity and protein yield, of soluble
rVP1GFP (estimated through its specific fluorescence)
(Figure 5) evolved contrarily to the resulting protein
amount in cells (Figure 2). This means that those con-
ditions that favour protein solubility are those giving
non-optimal results regarding conformational quality.
Interestingly, such a divergence between protein yield
and quality has been previously described in recombin-
ant E. coli [29,35], but the present finding confirms this
fact as a generic event.
Growth temperature
Finally, we determined how the production at subopti-
mal temperatures might influence solubility and con-
formational quality, through fluorescence determination
ab
Figure 1 Optical microscopy images (left) and fluorescence microscopy images (right) of L. lactis NZ9000 overproducing rVP1GFP
protein at 30°C 3h post-induction under a) hemin-stimulated respiration and b) anaerobic conditions. Fluorescent protein aggregates are
observed as highly fluorescent dots in the cell cytoplasm.
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protein produced at 25°C was similar to that obtained at
30°C. However, the specific fluorescence at 30°C was
notably higher than that observed at 25°C, showing in
this last condition a 6-fold increase and 1.6-fold increase
for the soluble and insoluble fraction respectively. At
16°C we observed a decrease in the fluorescence of both
soluble and insoluble protein fractions. On the other
hand, while the specific activity of the insoluble protein at
16°C was practically the same than that obtained at 30°C,
the specific fluorescence of the soluble fraction at 16°C
improved. Thus, decreasing the production temperature
did not result in any improvement of fluorescence
emission of insoluble protein, which was highly fluores-
cent at 30°C. In this direction, we also observed residualFigure 2 Fluorescence at 1, 3 and 5 h post-induction of soluble rVP1G
lactis NZ9000 at 30°C.enzymatic activity in the insoluble fraction of catalase-
producing cells (6.5 μmol/min/μg) (data not shown).
Discussion
Under the need to obtain LPS-free bacterial-derived
products for biomedical applications, the use of Gram-
positive microorganisms as a recombinant cell factory
has progressively gained relevance [12]. In this context,
an increasing number of approaches using LAB and
other Gram-positive microorganisms [9], have proven
the huge potential of these cell factories in recombinant
protein production [12,36-38]. Although L. lactis has
been widely explored as a cell platform for the produc-
tion of both homologous and heterologous recombinant
proteins [39-41], as far as we know, the solubility andFP (white bars) and insoluble rVP1GFP (grey bars) produced in L.
Figure 3 Yield of soluble (white bars) and IB rVP1GFP (grey bars) produced in L. lactis NZ9000 at 30°C.
Cano-Garrido et al. Microbial Cell Factories  (2014) 13:167 Page 4 of 7fine conformational quality of both soluble and insoluble
recombinant protein has been never studied in detail in
this microorganism.
In the present study, we provide data in line with pre-
vious studies that describe that fermentative growth is
the optimal condition to successfully produce recombin-
ant proteins in L. lactis (Figure 1) [32,33]. Thus, al-
though hemin-stimulated respiration has been described
as an alternative growth condition inducing an increase
in biomass and reducing media acidification [42], our re-
sults clearly show that under this condition protein pro-
duction is highly compromised in both soluble and
insoluble protein fractions. These data are in agreement
with previous results published. Specifically, the authors
describe the reduction of recombinant protein produc-
tion under aerobic conditions in the presence of hemin,
when compared to that obtained under similar condi-
tions without aeration [32,33].
Growth temperature also plays a key role regulating pro-
tein solubility and conformational quality. In this regard,Figure 4 Western blot of soluble and insoluble rVP1GFP fractions pro
3: insoluble rVP1GFP (replica 2), 4: insoluble rVP1GFP (replica 3), 5: soluble r
(replica 3), 8-12: standard curve (750, 500, 250, 125 and 75 ng of R9-GFP). T
observed around 20 KDa corresponds to GFP.protein activity is negatively affected at low temperatures,
but the conformational quality of soluble protein reaches
higher values at suboptimal temperatures, especially at
16°C. On the contrary, specific activity of insoluble protein
is poorly influenced by the temperature.
Conclusions
Recombinant protein quality in Lactococcus lactis is
largely influenced by the metabolic regime, growth con-
ditions and temperature. By controlling these parame-
ters, the conformational quality of both soluble and
insoluble protein fractions is widely modulated, what of-
fers a desirable high versatility of this system for the pro-
duction of endotoxin-free conventional soluble protein
and protein aggregates of biomedical interest. Beyond
the well-recognized ability of this system as a producer
of soluble proteins, the wide range of conformational
quality of the model protein prompts the further exploit-
ation of external effectors as efficient solubility modula-
tors for optimal yields.duced in L. lactis NZ9000. 1: Marker, 2: insoluble rVP1GFP (replica 1),
VP1GFP (replica 1), 6: soluble rVP1GFP (replica 2), 7: soluble rVP1GFP
he band around 50 Kda corresponds to VP1GFP , while the band
Figure 5 Specific fluorescence of soluble (white bars) and insoluble (grey bars) rVP1GFP produced in L. lactis NZ9000 at 30°C.
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Bacterial strain, plasmids and growth conditions
The Lactococcus lactis strains used in this study was
NZ9000 (pepN::nisRnisK) (NIZO). A model recombinant
protein rVP1GFP (a fusion between the VP1 capsid pro-
tein from the food-and-mouth disease virus and the
Green Fluorescent Protein) and human catalase (hcata-
lase) were produced by expressing the encoding gene
from the CmR pNZ8148 plasmid (NIZO) under nisA
promoter control.Plasmid construction
The rVP1GFP and hcatalase sequences were codon opti-
mized (Geneart). In the sequence design we added a
NcoI restriction site at 5’ followed by nucleotides CA to
restore the reading frame and an PstI restriction site at
3’ for rVP1GFP and XbaI for hcatalase. rVP1GFP gene
was digested by NcoI and PstI, and ligated into the NcoI-
PstI fragment of the expression plasmid pNZ8148. hca-
talase gene was digested by NcoI and XbaI, and ligated
into the NcoI-XbaI fragment of the expression plasmid
pNZ8148. Ligation products were transformed by elec-
troporation into L. lactis competent cells and positive
colonies were isolated by antibiotic selection.Table 1 Effect of growth temperature on protein
solubility and conformational quality
Fluorescence
(A.U./ml · OD) %
Specific fluorescence
(A.U./μg) %
30°C Soluble fraction 18,32 59,40
Insoluble fraction 81,68 40,60
25°C Soluble fraction 15,19 26,26
Insoluble fraction 84,81 73,74
16°C Soluble fraction 0,02 68,09
Insoluble fraction 99,98 31,91Preparation of L. lactis competent cells
A protocol to prepare competent L. lactis was developed
based on previous data [43]. L. lactis was growth O/N at
30°C in 50 ml M17 broth media enriched with 0.5% glu-
cose, 2% glycine, 0.5 M sucrose (G-SGM17B) and appro-
priated antibiotics. Then, 400 ml of G-SGM17B medium
were inoculated with an aliquot of the overnight culture
to reach an OD550 nm = 0.05 and they were grown at 30°C
during around 3h until the OD550 nm reached 0.2-0.3.
Then, cells were harvested by centrifugation at 10,000 g
for 20 min at 4°C and the pellet was resuspended in 400
ml of 0.5 M sucrose plus 10% glycerol. Samples were har-
vested again at 10,000 g for 10 min at 4°C, and the pellet
was washed in 200 ml of 0.5 M sucrose plus 10% glycerol
and 50 mM EDTA and formed again at 10,000 g for 10
min and 4°C. Cells were resuspended in 100 ml of 0.5 M
sucrose plus 10% glycerol, and pelleted by last time at
10,000 g for 10 min at 4°C. Finally, the sediment was
suspended in 4 ml of 0.5 M sucrose plus 10% glycerol,
aliquoted and stored at -80°C until used in transformation
experiments.Transformation
Electroporation was performed using Gene Pulser from
Bio-rad fitted with 2500V, 200 Ω and 25 μF in a pre-
cooled 2 cm electroporation cuvette. Following, samples
were supplemented with 900 μl restorative medium
(M17 broth with 0.5% Glucose, 20 mM Mg2Cl2 and 2
mM Ca2Cl2) and incubated for 2h at 30°C. The electro-
poration mix was centrifuged for 10 min at 10,000 g at
4°C and the pellet was resuspended in 100-200 μl of
M17 media and plated.Recombinant protein production
A pre-inoculum was prepared from a fresh colony of the
recombinant cells the pre-inoculum was used to inocu-
late 250 ml shake flasks. The cells were cultured as
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was used for plasmid maintenance and an agitation of 250
rpm was used for those cultures grown under hemin-
stimulated respiration.
Expression of the target gene was induced when the
optical density reached a value of 0.5 with nisin, as de-
scribed in [17,44]. Growth temperatures in the produc-
tion phase were 30, 25 or 16°C. Samples were taken at 1,
3 and 5 h in cultures at 30°C and at 5 h post-induction
in cultures grown at 25°C and 16°C.
All the experiments have been run in triplicate (replica
1, replica 2 and replica 3).Protein fractioning
Samples of 10 ml were taken in triplicate from bacteria
cultures. Cells were pelleted by centrifugation at 10,000
g at 4°C for 10 min and the sediment was resuspended
in 1 ml phosphate buffered saline (PBS) supplemented
with (Complete EDTA-free, Roche) to prevent proteoly-
sis. Then, ice-jacketed samples were disrupted by sonic-
ation (3 cycles of 5 min at 40% amplitude under 0.5 s
cycles). Total cell extracts were centrifuged at 15,000 g
and 4°C for 15 min. Finally, soluble and insoluble frac-
tions were aliquotated until further analysis.Protein determination
Soluble and insoluble protein fractions were analysed by
denaturing SDS-PAGE (10% acrylamide). Samples were
resuspended with denaturing buffer (Laemli 4x: Tris base
1.28 g, glycerol 8 ml, SDS 1.6 g, β-mercaptoethanol 4 ml,
urea 9.6 g in 100 ml) [45]. Soluble and insoluble protein
fractions were boiled for 5 and 45 min respectively. At
that time, samples were loaded onto the gel. SDS-PAGE
protein bands were electroblotted onto nitrocellulose
membranes and identified using a commercial poly-
clonal serum against GFP (GFP (FL): SC-833, Santa
Cruz Biotechnology). The secondary antibody was an
anti‐rabbit (Goat Anti-Rabbit IgG (H + L)-HRP Conju-
gate #172-1019, Bio Rad). The amounts of recombinant
protein were estimated by comparison with known
amounts (usually ranging from 75 to 750 ng) of R9-
GFP [46] or commercial hcatalase (Sigma Ref. C9322).
Densitometric analyses of the bands were performed
with the Quantity One software.Fluorimetry
Fluorescence emission (510 nm) was determined by
fluorimetry using a Cary Eclipse Fluorescence Spectro-
photometer (Variant), by using an excitation wavelength
of 450 nm, to measure protein fluorescence at soluble
and insoluble protein.Catalase activity assay
Catalase activity was determined by the Catalase Assay
kit (Abcam Ref. ab83464). In the assay H2O2 was added
to the catalase samples in order to measure the uncon-
verted H2O2 which reacts with OxiRed™. Reaction final
product was measured at Ex/Em = 535/587 nm by Victor
3 Multilabel Plates Reader. Catalase activity is reversely
proportional to the signal.
Microscopy
Samples of 1 ml were taken from bacteria cell culture by
triplicate and harvested by centrifugation at 10,000 g
and 4°C for 10 min. Cells were fixed with 0.1% formalde-
hyde in PBS and kept at 4°C until microscopy observa-
tion. Fixed cells were deposited on a glass slide fixed
with a slide cover and observed with a Leica DRMB
Microscopy. Microphotographies were taken by phase
contrast and epifluorescense.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EGF and AV designed this study and drafted the manuscript. OCG performed
most of the experiments and prepared the final data and figures. FR carried
out protein production and quantification at 25°C and LSG performed part
of protein fractioning and determination experiments. LRA and RB have
been involved in the experimental design. All authors read and approved
the final version of the manuscript.
Acknowledgments
The authors acknowledge the financial support granted to EGF and AV from
INIA, MINECO, Spain (RTA2012-00028-C02-02), from Agència de Gestió d’Ajuts
Universitaris i de Recerca (2014SGR-132) and from the Centro de Investigación
Biomédica en Red (CIBER) de Bioingeniería, Biomateriales y Nanomedicina
financed by the Instituto de Salud Carlos III with assistance from the European
Regional Development Fund. OCG received a PhD fellowship from MECD and
F.R. was supported by a predoctoral fellowship (Beca de Formación Doctoral
“Francisco José de Caldas”, Concovatoria 512-2010 de Colciencias). AV has been
distinguished with an ICREA ACADEMIA Award. We are also indebted to the
Protein Production Platform (CIBER-BBN) for helpful technical assistance and
for protein production and purification services (http://www.ciber-bbn.es/
es/programas/89-plataforma-de-produccion-de-proteinas-ppp).
Author details
1Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de
Barcelona, Bellaterra 08193, Cerdanyola del Vallès, Spain. 2Departament de
Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra
08193, Cerdanyola del Vallès, Spain. 3CIBER de Bioingeniería, Biomateriales y
Nanomedicina (CIBER-BBN), Bellaterra 08193 Cerdanyola del Vallès, Spain.
4Spherium Biomed S.L., Avda. Joan XXIII, 10, 08950, Esplugues de Llobregat
Barcelona, Spain.
Received: 21 October 2014 Accepted: 15 November 2014
References
1. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E, Villaverde A:
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact
2009, 8:17.
2. Demain AL, Vaishnav P: Production of recombinant proteins by microbes
and higher organisms. Biotechnol Adv 2009, 27:297–306.
3. Corchero JL, Gasser B, Resina D, Smith W, Parrilli E, Vazquez F, Abasolo I,
Giuliani M, Jäntti J, Ferrer P, Saloheimo M, Mattanovich D, Schwartz S Jr,
Tutino ML, Villaverde A: Unconventional microbial systems for the cost-
Cano-Garrido et al. Microbial Cell Factories  (2014) 13:167 Page 7 of 7efficient production of high-quality protein therapeutics. Biotechnol Adv
2013, 31:140–153.
4. Williams SF, Martin DP, Horowitz DM, Peoples OP: PHA applications:
addressing the price performance issue: I. Tissue engineering. Int J Biol
Macromol 1999, 25:111–121.
5. Parlane NA, Grage K, Lee JW, Buddle BM, Denis M, Rehm BH: Production of
a particulate hepatitis C vaccine candidate by an engineered
Lactococcus lactis strain. Appl Environ Microbiol 2011, 77:8516–8522.
6. de Marco A, Sevastsyanovich YR, Cole JA: Minimal information for protein
functional evaluation (MIPFE) workshop. N Biotechnol 2009, 25:170.
7. de Marco A: Minimal information: an urgent need to assess the
functional reliability of recombinant proteins used in biological
experiments. Microb Cell Fact 2008, 7:20.
8. de Marco A: Recombinant polypeptide production in E. coli: towards a
rational approach to improve the yields of functional proteins. Microb
Cell Fact 2013, 12:101.
9. Ferrer-Miralles N, Villaverde A: Bacterial cell factories for recombinant
protein production; expanding the catalogue. Microb Cell Fact 2013,
12:113.
10. Chen R: Bacterial expression systems for recombinant protein
production: E. coli and beyond. Biotechnol Adv 2012, 30:1102–1107.
11. Yuvaraj S, Peppelenbosch MP, Bos NA: Transgenic probiotica as drug
delivery systems: the golden bullet? Expert Opin Drug Deliv 2007, 4:1–3.
12. Garcia-Fruitos E: Lactic Acid Bacteria: a promising alternative for
recombinant protein production. Microb Cell Fact 2012, 11:157.
13. Hazebrouck S, Oozeer R, Adel-Patient K, Langella P, Rabot S, Wal JM, Corthier
G: Constitutive delivery of bovine beta-lactoglobulin to the digestive
tracts of gnotobiotic mice by engineered Lactobacillus casei. Appl Environ
Microbiol 2006, 72:7460–7467.
14. Vandenbroucke K, Hans W, Van HJ, Neirynck S, Demetter P, Remaut E,
Rottiers P, Steidler L: Active delivery of trefoil factors by genetically
modified Lactococcus lactis prevents and heals acute colitis in mice.
Gastroenterology 2004, 127:502–513.
15. Pontes DS, de Azevedo MS, Chatel JM, Langella P, Azevedo V, Miyoshi A:
Lactococcus lactis as a live vector: heterologous protein production and
DNA delivery systems. Protein Expr Purif 2011, 79:165–175.
16. de Ruyter PG, Kuipers OP, de Vos WM: Controlled gene expression
systems for Lactococcus lactis with the food-grade inducer nisin. Appl
Environ Microbiol 1996, 62:3662–3667.
17. Mierau I, Kleerebezem M: 10 years of the nisin-controlled gene expression
system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005,
68:705–717.
18. Jorgensen CM, Madsen SM, Vrang A, Hansen OC, Johnsen MG:
Recombinant expression of Laceyella sacchari thermitase in Lactococcus
lactis. Protein Expr Purif 2013, 92:148–155.
19. Jorgensen CM, Vrang A, Madsen SM: Recombinant protein expression in
Lactococcus lactis using the P170 expression system. FEMS Microbiol Lett
2014, 351:170–178.
20. Llull D, Poquet I: New expression system tightly controlled by zinc
availability in Lactococcus lactis. Appl Environ Microbiol 2004, 70:5398–5406.
21. Stentz R, Bongaerts RJ, Gunning AP, Gasson M, Shearman C: Controlled
release of protein from viable Lactococcus lactis cells. Appl Environ
Microbiol 2010, 76:3026–3031.
22. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B,
Cox E, Remon JP, Remaut E: Biological containment of genetically
modified Lactococcus lactis for intestinal delivery of human interleukin
10. Nat Biotechnol 2003, 21:785–789.
23. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van
Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L: A phase I trial with
transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin
Gastroenterol Hepatol 2006, 4:754–759.
24. Rodriguez-Carmona E, Villaverde A: Nanostructured bacterial materials for
innovative medicines. Trends Microbiol 2010, 18:423–430.
25. Portilla-Arias JA, Camargo B, Garcia-Alvarez M, de Ilarduya AM, Munoz-
Guerra S: Nanoparticles made of microbial poly(gamma-glutamate)s for
encapsulation and delivery of drugs and proteins. J Biomater Sci Polym Ed
2009, 20:1065–1079.
26. Parlane NA, Wedlock DN, Buddle BM, Rehm BHA: Bacterial Polyester
Inclusions Engineered To Display Vaccine Candidate Antigens for Use as
a Novel Class of Safe and Efficient Vaccine Delivery Agents. Appl Environ
Microbiol 2009, 75:7739–7744.27. Peterbauer C, Maischberger T, Haltrich D: Food-grade gene expression in
lactic acid bacteria. Biotechnol J 2011, 6:1147–1161.
28. Duwat P, Sourice S, Cesselin B, Lamberet G, Vido K, Gaudu P, Le Loir Y,
Violet F, Loubière P, Gruss A: Respiration capacity of the fermenting
bacterium Lactococcus lactis and its positive effects on growth and
survival. J Bacteriol 2001, 183:4509–4516.
29. Garcia-Fruitos E, Martinez-Alonso M, Gonzalez-Montalban N, Valli M,
Mattanovich D, Villaverde A: Divergent genetic control of protein
solubility and conformational quality in Escherichia coli. J Mol Biol 2007,
374:195–205.
30. de Groot NS, Ventura S: Effect of temperature on protein quality in
bacterial inclusion bodies. FEBS Lett 2006, 580:6471–6476.
31. Vera A, Gonzalez-Montalban N, Aris A, Villaverde A: The conformational
quality of insoluble recombinant proteins is enhanced at low growth
temperatures. Biotechnol Bioeng 2007, 96:1101–1106.
32. Berlec A, Tompa G, Slapar N, Fonovic UP, Rogelj I, Strukelj B: Optimization
of fermentation conditions for the expression of sweet-tasting protein
brazzein in Lactococcus lactis. Lett Appl Microbiol 2008, 46:227–231.
33. Oddone GM, Lan CQ, Rawsthorne H, Mills DA, Block DE: Optimization of
fed-batch production of the model recombinant protein GFP in
Lactococcus lactis. Biotechnol Bioeng 2007, 96:1127–1138.
34. Garcia-Fruitos E, Gonzalez-Montalban N, Morell M, Vera A, Ferraz RM, Aris A,
Ventura S, Villaverde A: Aggregation as bacterial inclusion bodies does
not imply inactivation of enzymes and fluorescent proteins. Microb Cell
Fact 2005, 4:27.
35. Martinez-Alonso M, Garcia-Fruitos E, Villaverde A: Yield, solubility and
conformational quality of soluble proteins are not simultaneously
favored in recombinant Escherichia coli. Biotechnol Bioeng 2008,
101:1353–1358.
36. van Dijl JM, Hecker M: Bacillus subtilis: from soil bacterium to super-
secreting cell factory. Microb Cell Fact 2013, 12:3.
37. Khokhlova EV, Efimov BA, Kafarskaia LI, Shkoporov AN: Heterologous
expression of secreted biologically active human interleukin-10 in
Bifidobacterium breve. Arch Microbiol 2010, 192:769–774.
38. Karlskas IL, Maudal K, Axelsson L, Rud I, Eijsink VG, Mathiesen G:
Heterologous protein secretion in lactobacilli with modified pSIP vectors.
PLoS One 2014, 9:e91125.
39. Noreen N, Hooi WY, Baradaran A, Rosfarizan M, Sieo CC, Rosli MI, Yusoff K,
Raha AR: Lactococcus lactis M4, a potential host for the expression of
heterologous proteins. Microb Cell Fact 2011, 10:28.
40. Kunji ER, Slotboom DJ, Poolman B: Lactococcus lactis as host for
overproduction of functional membrane proteins. Biochim Biophys Acta
2003, 1610:97–108.
41. Rigoulay C, Poquet I, Madsen SM, Gruss A: Expression of the
Staphylococcus aureus surface proteins HtrA1 and HtrA2 in Lactococcus
lactis. FEMS Microbiol Lett 2004, 237:279–288.
42. Gaudu P, Vido K, Cesselin B, Kulakauskas S, Tremblay J, Rezaiki L, Lamberret
G, Sourice S, Duwat P, Gruss A: Respiration capacity and consequences in
Lactococcus lactis. Antonie Van Leeuwenhoek 2002, 82:263–269.
43. Gerber SD, Solioz M: Efficient transformation of Lactococcus lactis IL1403
and generation of knock-out mutants by homologous recombination.
J Basic Microbiol 2007, 47:281–286.
44. Ng DT, Sarkar CA: Nisin-inducible secretion of a biologically active single-
chain insulin analog by Lactococcus lactis NZ9000. Biotechnol Bioeng
2011, 108:1987–1996.
45. Laemmli UK: Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 1970, 227:680–685.
46. Vazquez E, Roldan M, Diez-Gil C, Unzueta U, Domingo-Espin J, Cedano J,
Conchillo O, Ratera I, Veciana J, Daura X, Ferrer-Miralles N, Villaverde A:
Protein nanodisk assembling and intracellular trafficking powered by an
arginine-rich (R9) peptide. Nanomedicine (Lond) 2010, 5:259–268.
